BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.432
-0.021 (-4.55%)
Nov 7, 2024, 1:27 PM EST - Market open

Company Description

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.

The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.

BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd.
BioLineRx logo
Country Israel
Founded 2003
IPO Date Jul 25, 2011
Industry Biotechnology
Sector Healthcare
Employees 79
CEO Philip Serlin

Contact Details

Address:
Modi’in Technology Park, 2 HaMa’ayan Street
Hevel Modi'in, 7177871
Israel
Phone 972 8 642 9100
Website biolinerx.com

Stock Details

Ticker Symbol BLRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001498403
CUSIP Number 09071M205
ISIN Number US09071M2052
SIC Code 2834

Key Executives

Name Position
Philip A. Serlin CPA, M.B.A., CPA, MBA Chief Executive Officer
Mali Zeevi CPA, CPA Chief Financial Officer
Dr. Ella Sorani Ph.D. Chief Development Officer
Holly W. May M.B.A. President of BioLineRx USA
John Lacey Head of Corporate Communications and Investor Relations
Tsipi Keren-Lehrer B.Sc., L.L.B. Head of BD and Strategic Advisor
Raziel Fried Treasurer and Budgetary Control Director

Latest SEC Filings

Date Type Title
Nov 5, 2024 6-K Report of foreign issuer
Oct 16, 2024 6-K Report of foreign issuer
Oct 1, 2024 6-K Report of foreign issuer
Aug 19, 2024 6-K Report of foreign issuer
Aug 15, 2024 6-K Report of foreign issuer
Jun 18, 2024 6-K Report of foreign issuer
May 30, 2024 6-K Report of foreign issuer
May 28, 2024 6-K Report of foreign issuer
May 24, 2024 6-K Report of foreign issuer
May 17, 2024 6-K Report of foreign issuer